What Is Verrica Pharmaceuticals Inc. (VRCA) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Verrica Pharmaceuticals Inc.'s intrinsic value is estimated at $1.81. Trading at its current price of $5.66, the valuation engine raises significant caution: 7 of 8 models flag downside risk, projecting an average implied return of -68.1%. The most optimistic model, PWERM, places fair value at $6.45 (+13.9%), while Sentiment SOTP — the most conservative — estimates $0.08 (-98.5%). This +112.5% gap reflects genuine analytical uncertainty about Verrica Pharmaceuticals Inc.'s intrinsic worth.
What Do the Models Say About VRCA?
8 of 13 models are currently active for VRCA. Of these, 1 model suggests upside while 7 models suggest overvaluation. The Bayesian DCF estimates VRCA's intrinsic value at $0.98, implying -82.8% downside from the current price. See which stocks rank higher →
How Does VRCA Rank in Pharmaceutical Preparations?
Among 431 Pharmaceutical Preparations stocks, VRCA ranks #184 by Quality of Company score. CirclFi's QOC score of 5.2/10 evaluates 32 fundamental signals. A score of 5.2 reflects mixed fundamentals.
See all Most Undervalued Pharmaceutical Preparations Stocks →
The Pharmaceutical Preparations sector introduces analytical considerations specific to pharmaceutical industry businesses. For Verrica Pharmaceuticals Inc., metrics like biosimilar competition timeline provide important context that general-purpose valuation models may underweight.
Is VRCA a Value Trap?
CirclFi's Value Trap algorithm assigns VRCA a score of 32/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
8 of 13 models are active for Verrica Pharmaceuticals Inc.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Deep Alpha Valuation Engine, Verrica Pharmaceuticals Inc. scores 5.2 out of 10 on our 32-signal quality assessment, a moderate rating that shows mixed signals across our quality framework with notable weaknesses. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.
The gap between the most bullish and bearish model spans +112.5% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every VRCA valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across VRCA's 8 active models, average confidence is 25%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad